A Phase 2, multicenter, open label, two parts clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 (IDH1) mutant glioma
Study of Safusidenib in Patients with Brain Glioma
Sponsor: AnHeart Therapeutics Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU6265
U.S. Govt. ID: NCT05303519
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved.
Investigator
Fabio Iwamoto, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have a life expectancy of more than 3 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE